Biogen CEO Chris Viehbacher, the company's intercontinental director, Fraser Hall, and the Biogen Brazil team met today with Abahe representative Amália Maranhão to hear the story of building the Friedreich's Ataxia community in Brazil.

Pharmaceutical company Biogen has asked Anvisa for a license to register and market in Brazil the first drug for the treatment of the ultra-rare neurodegenerative disease *Friedreich's Ataxia* called Skyclarys.